Mauro Loi
isteddos.bsky.social
Mauro Loi
@isteddos.bsky.social
Radiation Oncologist, MD PhD
Pinned
Hora Est! So grateful to Erasmus MC for granting me the opportunity to defend my PhD on 10/12/2024! Thanks to my beautiful paranymphs Linda Rossi and Alba Magallón Baro and promoters Prof Hoogeman and Dr Nuyttens! Thanks to all my friends for being there ❤️
Reposted by Mauro Loi
Today he's on fire!
July 13, 2025 at 11:16 AM
Reposted by Mauro Loi
In case you may have missed any of the

Virtual Grand Rounds in Radiation Oncology lectures

Recordings are 👇
youtube.com/playlist?lis...

Endorsed by:
ESTRO
DEGRO
SASRO
December 5, 2024 at 2:12 PM
Reposted by Mauro Loi
Fresh from #ASCO2025
meetings.asco.org/abstracts-pr...
SBRT vs microwave ablation (MWA) in pts with CRC liver oligo-mets
➡️ n=100, n=92 treated (39 SBRT, 53 MWA)
➡️ 18/92 pts (20%) reported side effects
➡️ n=3 G3-4 pain; n=2 infections after open MWA, n=1 bowelperforation after percutaneous MWA
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 25, 2025 at 8:28 AM
Proud to contribute to this important study on TNT for rectal cancer led by Francesco Sclafani 👇

pubmed.ncbi.nlm.nih.gov/40638097/
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer - PubMed
The findings of this case series study show substantial variation in the choice of the TNT regimen and were overall aligned with those reported in clinical trials, suggesting the efficacy of TNT in a ...
pubmed.ncbi.nlm.nih.gov
July 20, 2025 at 1:52 PM
Ureter tolerance to SBRT: challenging current dose constraints! Great collaboration led by Lucy Van Werkhoven 👇

linkinghub.elsevier.com/retrieve/pii...
Redirecting
linkinghub.elsevier.com
July 20, 2025 at 1:50 PM
Bayesian Design in a nutshell #GI25
January 24, 2025 at 10:00 PM
Great presentation by Nina Niu Sanford on the role of RT in multimodal management of esophageal cancer
January 24, 2025 at 12:17 AM
Great presentation on TNT applicability in Gastric Cancer by Travis Grotz (Mayo Clinics) #GI25
January 23, 2025 at 7:03 PM
Florence Radiation Oncology team at ASCO GI25!
January 23, 2025 at 6:14 PM
Maintaining first-line therapy plus radiotherapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma - International Journal of Radiation Oncology, Biology, Physics www.redjournal.org/article/S036...
Maintaining first-line therapy plus radiotherapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma
: Optimal treatment strategies for patients with hepatocellular carcinoma (HCC) with oligoprogression after first-line systemic therapy (FLST) remain undefined. We aimed to determine if maintaining [i...
www.redjournal.org
January 21, 2025 at 5:27 PM
Reposted by Mauro Loi
Because crossposting on X + BlueSky is all the rage😂...

Excited, & grateful🙏, to have my first ever #RedJournal Podcast in the👜

Also happened to be only the SECOND #RadBio Podcast ever❓Clearly we need to ⬆️ that😅 #RadBio4TheMasses

Stay tuned‼️
🙏

➡️https://www.redjournal.org/multimedia/audio
January 19, 2025 at 7:13 PM
"Chi sa fa, chi non sa fare coordina". Poor decision making in the hands of incompetent, inept management spiraled into the current situation

t.co/zln79XdRPe
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00375-2/fulltext
t.co
January 6, 2025 at 8:52 AM
Hora Est! So grateful to Erasmus MC for granting me the opportunity to defend my PhD on 10/12/2024! Thanks to my beautiful paranymphs Linda Rossi and Alba Magallón Baro and promoters Prof Hoogeman and Dr Nuyttens! Thanks to all my friends for being there ❤️
December 14, 2024 at 10:24 AM
Single-modality endocrine therapy versus #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #BreastCancer (EUROPA)
@TheLancetOncol

▶️ Share Link – 50 days' free access to the article (Jan 31, 2025):
t.co/jedNdGzeE7
December 14, 2024 at 10:09 AM
December 1, 2024 at 3:19 PM